Atglistatin
SIGMA/SML1075 - ≥98% (HPLC)
Synonym: 3-(4′-(Dimethylamino)-[1,1′-biphenyl]-3-yl)-1,1-dimethylurea
Empirical Formula (Hill Notation): C17H21N3O
Molecular Weight: 283.37
MDL Number: MFCD28009494
Linear Formula: C17H21N3O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C17H21N3O/c1-19(2)16-1 |
| InChI key | AWOPBSAJHCUSAS-UHFFFAOYSA |
| Quality Level | 100  |
| SMILES string | CN(C)C(NC1=CC=CC(C2=CC=C( |
| solubility | DMSO: 20 mg/mL, clear |
| storage temp. | 2-8°C |
| Application: | Atglistatin has been used as a selective inhibitor of adipose triglyceride lipase (ATGL). |
| Biochem/physiol Actions: | Atglistatin is the first selective inhibitor of adipose triglyceride lipase (ATGL), the rate limiting enzyme involved in the mobilization of fatty acids from cellular triglyceride stores. Atglistatin has an IC50 of 0.7 μM in E.coli and no activity against monoglycerol lipase (MGL), hormone-sensitive lipase (HSL), or pancreatic lipase and lipoprotein lipase PNPLA6 and PNPLA7. ATGL generates diacylglycerol from cellular triglyceride stores, which is then degraded by hormone-sensitive lipase (HSL) and monoglyceride lipase into glycerol and fatty acids, promoting the synthesis of lipotoxic metabolites that have been associated with the development of insulin resistance. Atglistatin inhibition of ATGL has been shown to reduce fatty acid mobilization in vitro and in vivo. |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |